process

Plato Data Intelligence Leverages Vectara to Power its Data-As-A-Service / DaaS Platform

Source Node:
Time Stamp: January 18, 2024 1:36 PM - Modified On: January 18, 2024 - Published By:
Source Cluster:
Republished By Plato

From development to launch, Vectara’s GenAI technology and team help innovators get to market faster. The announced partnership breaks new ground towards deploying a next generation of GenAI tools with Vertical focus. Vectara, the Trusted Generative AI Product Platform, and Plato Data Intelligence, creators of PlatoAi, have entered into a commercial agreement to unlock the power of Vectara via Plato AI’s Generative Intelligence platform. With an emphasis on secure, trustworthy, and transparent GenAI for enterprises, Vectara was the clear choice for developers who want a trusted provider to count on

Paribus Embracing DAO transition.

Source Node:
Time Stamp: December 22, 2023 3:10 PM - Modified On: December 22, 2023 - Published By:
Source Cluster:
Republished By Plato

In our journey of developing Paribus, we’ve received a lot of feedback from our community, primarily positive and helpful. But, as is often the case when a small team controls a platform, not everyone agrees with our decisions. At every step, we’ve tried to make the best choices based on the information we had. We’ve always known that, eventually, it would be the community’s turn to take the lead in guiding Paribus. And, as we announced in our recent X-space update, that time is approaching fast with the release of

Curio and Deep Isolation Sign MOU to Advance Nuclear Waste Disposal Technologies.

Source Node:
Time Stamp: December 7, 2023 3:23 PM - Modified On: December 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Washington, D.C, December 7, 2023 — Curio, a trailblazer in nuclear technology solutions, and Deep Isolation, an innovator in nuclear waste disposal, have entered into a Memorandum of Understanding (MOU) to collectively drive forward the development of advanced technologies for efficient and secure disposal of high-level nuclear waste (HLW). Under this MOU, both Curio and Deep Isolation will mutually collaborate and exchange critical information for the use of Deep Isolation’s Universal Canister System (UCS) and patented directional drilling solution for deep borehole disposal for the isolation and management of HLW

Walking the Tightrope

Source Node:
Time Stamp: November 15, 2023 5:19 AM - Modified On: November 15, 2023 - Published By:
Source Cluster:
Republished By Plato

As we stand on the verge of a new era in crypto, it’s crucial to reaffirm the importance of decentralization. Beyond being a mere aspiration, decentralization serves as the lifeblood of the crypto world, standing as the pivotal force that draws the line between freedom and control. Amidst the hype surrounding the impending approval of a spot Bitcoin ETF in the United States, accompanied by the influx of capital from behemoths like BlackRock, the immediate market surge raises a serious question for the future of crypto. Are people here for

HealthCare AI: The Unavoidable Revolution in Modern Medicine

Source Node:
Time Stamp: October 5, 2023 3:40 PM - Modified On: October 5, 2023 - Published By:
Source Cluster:
Republished By Plato

By Eric Greenberg www.linkedin.com/in/ericabg In the evolving landscape of medical technology, there's one force that stands head and shoulders above the rest, promising a seismic shift in the very ethos of healthcare delivery: Artificial Intelligence (AI). As a seasoned technology and banking analyst, it is my considered opinion that Healthcare AI isn't just a trend or a buzzword. It’s the very future of medicine, poised to reshape everything we know about patient care, disease diagnosis, and medical research. To begin with, the economic implications of integrating AI in healthcare are

Revolutionizing Clinical Trials: The Digital Watermarking and AI Duo

Source Node:
Time Stamp: October 5, 2023 11:22 AM - Modified On: October 5, 2023 - Published By:
Source Cluster:
Republished By Plato

Revolutionizing Clinical Trials: The Digital Watermarking and AI Duo Clinical trials, the linchpin of medical research, have long been riddled with inefficiencies, from patient recruitment bottlenecks to data management hurdles. As a technology and banking analyst, I've seen how digital solutions can overhaul entire sectors, offering improved productivity and streamlined processes. It's high time that clinical trials get a dose of such digital innovation, and there's a potent combination on the horizon: digital watermarking coupled with Artificial Intelligence (AI). At first glance, one might wonder: how can a technique often

Zilliqa partners with GMEX ZERO13 to launch consumer-focused carbon offset platform

Source Node:
Time Stamp: September 27, 2023 6:42 AM - Modified On: September 27, 2023 - Published By:
Source Cluster:
Republished By Plato

  LONDON, 27 September 2023 – Zilliqa, a leading layer-1 blockchain offering high-performance, high-security and low-fee solutions, today announces a partnership with GMEX Group and its initiative ZERO13, the digital climate fintech aggregation ecosystem, to launch the first-of-its-kind carbon offset platform that will transform the way that retail customers engage with corporate environmental initiatives. Together, Zilliqa Group and GMEX ZERO13 will deliver a cutting-edge platform that uses the blockchain-based currency, EVP, to represent carbon credit offsets. When they purchase goods or services, customers of brands partnered with Zilliqa will receive

Welcome Renal Warriors

Source Node:
Time Stamp: September 11, 2023 7:58 AM - Modified On: September 11, 2023 - Published By:
Source Cluster:
Republished By Plato

I am a 68 year old man born in Brooklyn, New York and living for decades in Ithaca, NY. I also have 10 years each with homes in @San Ramon, Costa Rica and @Austin, Texas. My present and future dreams are in #Africa and I am setting up a base in @CapeTown, South Africa. #notmytimetodie #supportmymiracle #childofimmigrants #latebloomer. I was told a year ago that I would certainly die if I did not have not follow the standard treatment of care. I rejected both dialysis and a transplant and am

American Picture House Corporate Update

Source Node:
Time Stamp: September 6, 2023 4:28 PM - Modified On: September 6, 2023 - Published By:
Source Cluster:
Republished By Plato

New York, NY, Raleigh, NC, and Los Angeles, CA.  September 6, 2023 – American Picture House Corporation (OTC: APHP), an entertainment company with a focus on producing feature films, limited series, and entertainment enhancing technologies, today provided a corporate update for shareholders. Industry Strikes American Picture House supports the ideals behind the two current industry strikes -- brought by the Writers Guild of America (“WGA”) and the Screen Actors Guild (“SAG”) -- and joins the many reasonable voices urging for a fair and timely resolution. Update on Feature Films -

The Collision of Titans: AI and Web3

Source Node:
Time Stamp: September 4, 2023 12:28 PM - Modified On: September 4, 2023 - Published By:
Source Cluster:
Republished By Plato

Over the past decade, two titans have emerged from the tech realm, each promising to redefine the very fabric of our global infrastructure - Artificial Intelligence (AI) and Web3. But what happens when these two forces converge? Are we on the brink of a new digital renaissance or a potentially uncharted dystopia? Consider this: AI is, at its core, the embodiment of advanced logic and decision-making, a machine's ability to "think" and process information in ways eerily similar to humans. It's no longer just about algorithms; it's about creating synthetic

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Source Node:
Time Stamp: August 29, 2023 8:20 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement